KAILERA THERAPEUTICS INC (KLRA)
NASDAQHealth CareBiotechnologySnapshot 2026-10-16
$11.25-3.93%
Close 2026-10-16 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-16
Research Workspace
Put KLRA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisThis stock is volatile — it swings about 3% on a typical day and fell roughly 62% in its worst 12-month stretch.
View RiskKLRA’s case rests on advancing ribupatide through global Phase 3 obesity trials. Revenue growth is unknown, and its latest recorded quarter missed estimates by 47.3%. The catalyst is trial progress, with Phase 3 enrollment now complete. No valuation multiple or priced-in expectations are available, so the market’s growth assumptions remain unclear. The specific risk is another miss: our model puts next-quarter miss probability near 65%. That risk matters after the latest large miss. Our standing thesis remains intact, and this read is provisional.
Trailing returns as of 2026-10-16. KLRA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering KLRA (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare KLRA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| KLRA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-16. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put KLRA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance ribupatide injection through global Phase 3 trials
Completion of enrollment is a significant milestone for Phase 3 trials.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-16. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
New leadership role may enhance corporate strategy.
Leadership change may improve strategic direction.
New appointment strengthens management team.
Positive clinical data supports product development.
Clinical data presentations enhance credibility.
Phase 2 trial success boosts product pipeline.
Initiation of Phase 3 trial indicates progress.